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Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are both relentlessly progressive and
ultimately fatal neurological disorders. ALS is familial in 10% of cases and FTD in 30%. Inheritance is usually
autosomal dominant with variable penetrance. Phenotypic overlap between ALS and FTD can occur within the
same kindred. Mutations in copper/zinc superoxide dismutase 1 (SOD1) are found in 20% of familial and 3%
of sporadic ALS cases but are not associated with dementia. Mutations in microtubule associated protein tau
(MAPT) are detected in 30% of familial FTD kindreds. Dominant ALS with FTD has previously been linked to
9q21 and pure ALS to loci on 16q21, 18q21, 20p13. Here we report the results of a genome-wide linkage study in
a large ALS and FTD kindred using Affymetrix 10KGeneChipmicroarrays. Linkage analysis of single nucleotide
polymorphism (SNP) data identified consistently positive log of the odds (LOD) scores across chromosome 9p
(maximal LOD score of 2.4). Fine mapping the region with microsatellite markers generated a maximal
multipoint LOD score of 3.02 (u = 0) at D9S1878. Recombination narrowed the conserved haplotype to
12 cM (11 Mb) at 9p13.2–21.3 (flanking markers D9S2154 and D9S1874). Bioinformatic analysis of the region
has identified 103 known genes.
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NPL = non-parametric linkage; SNP = single nucleotide polymorphism; SOD = superoxide dismutase
Received November 14, 2005. Revised January 11, 2006. Accepted January 13, 2006. Advance Access publication February 22, 2006.
Introduction
Amyotrophic lateral sclerosis (ALS) and frontotemporal
dementia (FTD) are both relentlessly progressive and ulti-
mately fatal neurological disorders. There is increasing
evidence that the two conditions can exist in a phenotypic
spectrum within individuals and within autosomal domi-
nant kindreds (Lipton, 2004). In ALS, motoneurons in the
motor cortex, brainstem and spinal cord degenerate. Muscle
wasting, weakness and spasticity usually starts in one limb
but over time becomes generalized, leading to profound
global paralysis. Death due to respiratory failure occurs on
average only 3 years after symptom onset and there is no
therapy that significantly alters the course of the disease
(Shaw et al., 2001). The pathological hallmark of ALS is
the presence of ubiquitinated inclusions in the perikaryon
and proximal axon of surviving motoneurons, but the
underlying disease mechanisms are poorly understood
(Leigh, 1989). The majority of cases are sporadic, but in
10% of patients there is a positive family history (FALS),
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typically with an autosomal dominant pattern of inheritance
and reduced penetrance (Strong, 1991). With few exceptions,
familial and sporadic ALS are indistinguishable on clinical
and pathological grounds (Shaw et al., 1997; Ince et al., 1998).
FTD is characterized at the outset by a personality change
and socially inappropriate behaviour, with relative preserva-
tion of memory and cognitive functions. Language defects
are common and may present with a semantic dementia or
non-fluent aphasia (Hodges, 2001). Eventually, there is a
more global cognitive deficit and death often due to immo-
bility and respiratory infection. Survival of pathologically
proven FTD is, on average, only 4 years from symptom
onset (Rascovsky, 2005). Pathologically, neurons in the
superficial frontal cortex and anterior temporal lobes degen-
erate. The molecular pathology of FTD has been divided into
at least three groups: a tauopathy, with neurofibrillary tangles;
ALS-like, with ubiquitinated and neurofilamentous inclu-
sions and the remainder lacking distinctive histopathological
features (Piguet, 2004). In 40% of FTD cases, there is a
family history of dementia, indicating a significant genetic
contribution (Rosso, 2003). In many sporadic and familial
FTD cases there is clinical and pathological evidence of an
overlap with ALS (Lipton, 2004).
Linkage to chromosome 21q22 (Siddique et al., 1991) led
to the identification of mutations in the Cu/Zn superoxide
dismutase (SOD) gene in ALS (SOD1, ALS1 OMIM 105400)
(Rosen, 1993). To date, over 109 SOD1 mutations have been
reported and can be detected in 20% of FALS and 3% of
sporadic ALS cases (Shaw et al., 1997; Andersen et al.,
2003). Mice transgenic for several different human SOD1
mutants develop progressive motoneuron degeneration
through a toxic gain of function (Gurney et al., 1994) unre-
lated to catalytic activity (Wang et al., 2003). Although
mutant SOD1 is ubiquitously expressed at high levels in
many tissues in patients and transgenic mice, degeneration
is largely confined tomotoneurons. Detergent-resistant SOD1
aggregates are detected in the spinal cord and enriched in their
mitochondrial fractions (Jonsson et al., 2004; Liu et al., 2004).
It has therefore been postulated that protein misfolding,
mitochondrial dysfunction and apoptosis may play a mech-
anistic role in the pathogenesis of ALS (Liu et al., 2004).
SOD1 has provided only one piece of the molecular jigsaw
puzzle, and progress in identifying other autosomal dominant
ALS genes has been slow. Linkage to 20q13 was identified in a
large Brazilian kindred with a slowly progressive adult-onset
form of spinal muscular atrophy (ALS8 OMIM 608627)
(Nishimura et al., 2004a). Mutations were subsequently
identified in the gene-encoding vesicle-associated membrane
protein B (VAPB) in the original and six other families
(Nishimura et al., 2004b). One of the VAPB kindreds has a
phenotype closer to ALS, with signs of upper and lower
motoneuron degeneration and a more rapid disease course.
One large Italian kindred with classical ALS affecting 20
individuals has been confidently linked to a locus on 18q21
with a maximal multipoint log of the odds (LOD) score of
4.5 and haplotype spanning 8 Mb, but a pathogenic mutation
has not yet been identified (ALS3, OMIM 606640) (Hand
et al., 2002). Another kindred demonstrated linkage to
20p13 with a maximal multipoint LOD score of 3.46 and a
shared haplotype of 1 Mb (ALS7, OMIM 608031) (Sapp
et al., 2003), but the strength of this linkage rests very much
on the parameters defining penetrance.
Kindreds with a phenotype encompassing features of FTD,
parkinsonism and ALS have been linked to 17q21 and muta-
tions have been identified in the microtubule associated pro-
tein tau (MAPT) (OMIM 157041) (Hutton et al., 1998). Tau
mutations can be detected in 25–30% of familial FTD kin-
dreds (Rosso, 2003; Stanford, 2004), but pathological muta-
tions in tau have not yet been described in kindreds with pure
ALS. Some families with dominant ALS have a phenotype that
overlaps with FTD. A locus for ALS–FTD has previously been
reported in five families at 9q21 (OMIM 105550) (Hosler,
2000), but no pathogenic mutations have been reported to
date. The clinical phenotype and genetic basis of the juvenile-
onset motoneuron disorders are also quite distinct, and no
linkage or association has been shown with classical adult-
onset ALS for ALS2 (2q33, OMIM 205100) (Hentati et al.,
1994), ALS4 (9q34, OMIM 602433) (Chance et al., 1998) or
ALS5 (15q15–21, OMIM 602099) (Hentati et al., 1998).
We have previously published the results of a genome-wide
microsatellite marker scan in a large English family (F1),
which demonstrated linkage to chromosome 16q12 with a
two-point LOD score of 3.61 (Ruddy et al., 2003). Concur-
rently, two other unrelated families were published demon-
strating linkage to an overlapping region on 16q12 with
multipoint LOD scores of 3.29 (Sapp et al., 2003) and 2.06
(Abalkhail, 2003), and the locus has been designated ALS6
(OMIM 608030). In our initial report we described a second
family (F2), which showed weaker linkage to the same region
with a two-point LOD score of 1.84 (Ruddy et al., 2003).
Subsequent to that publication, two members of the F2 kin-
dred have developed ALS. Neither shares the linked chromo-
some 16 haplotype with the earlier affected individuals, nor
the other newly affected person. Here we present data from
a genome-wide scan in this kindred using single nucleotide
polymorphism (SNP) arrays and fine mapping using micro-
satellite (STS) markers, which provides convincing evidence
of a novel locus on chromosome 9 for autosomal dominant
ALS with features of FTD.
Patients and methods
Kindred description and clinical phenotype
A large Dutch kindred with familial ALS was identified and followed
over a 20-year period (Fig. 1). There was no consanguinity and the
inheritance is consistent with an autosomal dominant pattern with
reduced penetrance (40% by the age of 70) as several obligate
carriers lived until their late 70 s). All but one affected, and many
unaffected individuals, were examined by one consultant neurologist
(VdeJ). The diagnosis of ALS in the unseen individual (II:5) was
made in retrospect by her relatives and from written correspondence,
which clearly describes a rapidly progressive muscle wasting illness.
Nine individuals in ALS in generations II and III had upper and
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lower motoneuron signs in at least three clinical regions and fulfilled
the El-Escorial Criteria of ‘Clinically Definite ALS’ (Brooks et al.,
2000) (Table 1). Electromyography (EMG) confirmed muscle dener-
vation, without evidence of conduction block in all eight individuals
who presented with ALS andwere tested. The site of disease onset was
evenly split between bulbar (five) and limb (five). Variability was
seen in the age at onset (mean of 62 years, range 40–72) and survival
(mean of 36 months, range 12–90).
Three individuals, who presented with motor symptoms of ALS,
subsequently developed personality and behavioural features during
their illness, but none underwent formal psychometric testing. III:2
became progressively apathetic, cognitively impaired and socially
isolated and was found to have frontotemporal atrophy at autopsy.
Another, III:5, became increasingly self-centred, unreasonable, emo-
tionally labile and uncooperative, which was not attributed to
mood disturbance. The third, III:7, developed paranoid visual and
Fig. 1 The diagram is a greatly abbreviated depiction of this kindred. Generation II contained 18 individuals (II:8 represents 13 siblings, two
of whom died in infancy) and not all siblings are shown in generations III and IV. Four branches of the family in these generations have
developed ALS and FTD. Symbols: pure ALS depicted in black, ALS and FTD combined by dark grey and FTD predominant by light grey.
Critical recombination events occur in the recreated individual III5. They are robust as the centromeric crossover is also present in two
siblings (III:6 and III:7) and the telomeric crossover is also present in three offspring (IV:3, IV:5 and IV:6).
Table 1 Clinical features and investigation results of affected individuals from Family F2 with ALS–FTD
Id Gender Age at
onset (years)
Survival
(months)
Site at
onset
El Escorial
category
Bulbar
symptoms
Psychiatric
symptoms
Denervation
on EMG
ALS on
autopsy
FTD on
autopsy
II:5 F 61 12 Bulbar ? ? ? N/A N/A N/A
III:1 F 70 32 Bulbar Definite +  Y +++ ++
III:2 M 72 33 Hand Definite + + Y +++ 
III:5 F 67 19 Bulbar Definite + + Y N/A N/A
III:7 F 67 36 Leg Definite + + Y N/A N/A
III:8 F 63 34 Bulbar Definite +  Y +++ 
III:11 M 58 36 Bulbar Definite +  N/A N/A N/A
III:12 M 67 36 Leg Definite +  Y N/A N/A
III:14 F 40 92 Hand Definite +  Y N/A N/A
III:16 M 59 32 Hand Definite +  Y +++ 
IV:1 F 39 31 Behaviour Possible + + Normal + ++
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auditory hallucinations with inappropriate behaviour. Although
mild cognitive and verbal fluency problems are not uncommon in
ALS, major behavioural and psychotic symptoms are highly unusual
and may reflect frontotemporal dysfunction.
One individual, IV:1, the offspring of the affected III:2, presented
at the age of 39 with a progressive dementia and died of respiratory
failure after 31 months. Her husband reported that she began
behaving in a childish manner, swearing and neglecting her house-
hold duties, had lost interest in her surroundings and had taken up
smoking—all of these behaviours were uncharacteristic. She was
admitted to a psychiatric hospital for investigation. Examination,
18 months after symptom onset, described a ‘wide-eyed, agitated,
affectively a childlike woman who perseverates. She has a very short
span of attention and repeatedly asks to be allowed to go out and
smoke cigarettes. She cries several times briefly but without tears.
She lacks insight and thinks that she is in the mental hospital because
of her nervousness at home’. Muscle wasting was present in the
interossei of both hands and fasciculations were noted in the
arms, hands and thighs. Deep tendon reflexes were within normal
limits but Hoffmann’s sign was strongly positive bilaterally. Plantar
responses were flexor. Limited EMG examination at this time was
normal. Anti-neuronal autoantibody screen was negative but MRI of
the brain revealed striking frontal lobe atrophy (Fig. 2). Examination
6 months later revealed an emaciated woman with little spontaneous
speech. Grasp reflexes were negative, but snout, pout and jaw jerk
reflexes were positive with tongue and limb fasciculation. Deep ten-
don reflexes in the limbs were all exaggerated with an extensor left
plantar response. The clinical diagnosis was of FTD and ALS.
One other individual (III:9) died from dementia and may well
have had FTD without clinical signs of ALS. He presented with
fearfulness, irascibility and violent behaviour, leading to his admis-
sion to a psychiatric hospital. He became increasingly withdrawn
and unresponsive and eventually died as an inpatient. Until just
prior to his death he had been ambulant and could speak, eat and
use his hands. As the information could not be verified frommedical
records and historical details were incomplete, we have not included
him in Table 1.
Pathological description
Five individuals underwent detailed pathological assessment; at
post-mortem significant upper and lower motoneuron degener-
ation was detected in all four cases who presented with ALS.
Ubiquitinated inclusions were detected in the anterior horn cells
in three of these individuals. Bunina bodies were detected in the
fourth case and one other who had Hirano bodies and mild front-
oparietal atrophy. One individual, who died from ALS at age 74
with no psychiatric symptoms, had occasional neurofibrillary tau
tangles, which were consistent with age. Interestingly, in this patient
the granular layer of the hippocampus showed ubiquitin-positive
(and tau-negative) inclusions that are characteristic for ALS-FTD.
No other cases had tau-positive inclusions. Post-mortem examina-
tion of the woman who presented with FTD (IV:1) showed striking
atrophy of the frontal lobes, precentral gyri and anterior roots of the
spinal cord. Light microscopy revealed occasional inclusion bodies
in Betz cells of the motor cortex and neuronophagia. Ubiquitinated
and nuerofilamentous inclusions were frequent in the granular cell
layer of the hippocampi, with features of neurodegeneration and
microglial activation. Tau staining revealed no Pick bodies, neuritic
tangles or other tau immunoreactive inclusions. Motoneurons in
the brainstem nuclei and spinal cord were shrunken with axonal
swellings and reactive gliosis, but no inclusions. Muscle pathology
confirmed neurogenic atrophy. The findings were reported as being
typical of FTD and ALS.
Recruitment and initial mutation screening
and linkage to known loci
Family members were contacted by the attending neurologist and
nurse. Following informed consent, blood was drawn from 148
family members. Ethical committees in both clinical centres have
approved genetic research on ALS. Blood samples were available
from eight affected individuals, and two more affected individuals
could be recreated by genotyping their unrelated spouses and off-
spring. DNA was extracted and mutations excluded in two affected
individuals by direct sequencing of the coding and flanking
Fig. 2 Brain MRI of a 40-year-old woman with an 18-month history of a progressive behavioral, language and cognitive disorder
(individual IV:1). (A) Axial T2-weighted image showing symmetrical widening of the frontal lobe sulci, sylvian fissures and anterior horns
of the lateral ventricles with relative sparing of the posterior cerebrum. (B) Coronal T2-weighted image showing striking frontal lobe
atrophy and an absence of signal change in the white matter of both hemispheres.
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sequences of SOD1 (Shaw et al., 1998) and VAPB (Nishimura et al.,
2004b). All the exons and intron/exon boundaries of gene encod-
ing MAPT were screened for mutations by direct sequencing in two
individuals (Rizzu, 1999). Furthermore, linkage to the MAPT locus
at chromosome 17q21 was confidently excluded by SNP linkage
analysis, which generated LOD scores of 5.0 (see graphs in
Supplementary material). Linkage to the other published loci—
ALS3 at 18q21, ALS6 at 16q12, ALS7 at 20p13 and ALS–FTD at
9q21—was excluded by genotyping the affected individuals for
informative microsatellite makers spanning these regions (data
not shown) and later confirmed by SNP linkage analysis.
Bioinformatics
The most informative members of the family for linkage were iden-
tified using Slink (Terwilliger, 1993) and modelled in a genome-
wide screen using the following assumptions: autosomal dominant
inheritance with age-dependent penetrance, no phenocopies, a dis-
ease gene frequency of 0.00001 and equal marker allele frequencies.
Liability classes were based on previously published reports (Hand
et al., 2001; Ruddy et al., 2002) and refined specifically to account for
the age-dependent penetrance of this family: (i) age < 46 years—20%
(ii) age > 46 years—40%; and (iii) spouses were given the back-
ground population risk. Ages were defined as the age at onset in
affecteds and the age at last review of asymptomatic individuals.
These assumptions were applied to linkage analysis of STS markers
using Mlink (Goldgar, 1992) and Allegro (Gudbjartsson, 2000).
Non-parametric linkage (NPL) analysis of SNP genotypes was per-
formed using Merlin (Abecasis et al., 2002). Because of the size of the
pedigree, it was initially split by setting individual II:6 (Fig. 1) as a
founder and run as two separate pedigrees and the scores were added.
LOD scores greater than 0.8 were regarded as requiring further
investigation. Genome-wide multipoint analysis of SNP data for a
reduced pedigree, containing affected individuals only, was per-
formed also using Merlin. In these regions, STS markers were geno-
typed and analysed using MLink, and Allegro STS genotypes were
imported into PedCheck (O’Connell and Weeks, 1998) to confirm
the correct inheritance of alleles. Haplotype analysis was performed
initially manually to ensure Mendelian inheritance of alleles. Publicly
accessible databases, including NCBI, Ensemble and UCSC, were
searched for known and putative genes. Known genes were defined
as those for which mRNA, expressed sequence tags (ESTs) or pro-
teins had been confidently identified.
Genotyping using SNP arrays
SNP genotyping was undertaken using the GeneChipMapping 10K
v2.0 Xba Array containing 10 204 SNP markers following the man-
ufacturer’s instructions (Affymetrix, Santa Clara, CA, USA). Briefly,
250 ng of genomic DNA from each sample was digested with the
restriction endonuclease XbaI for 2.5 h. Digested DNA was mixed
with Xba adapters and ligated using T4 ligase for 2.5 h. Ligated
DNA was added to four separate polymerase chain reactions
(PCR), amplified, pooled and purified to remove unincorporated
dNTPs. The purified PCR product was then fragmented with
DNase1, end-labelled with biotin and hybridized to an array for
18 h in an Affymetrix 640 hybridization oven. Arrays were then
washed and stained using an Affymetrix Fluidics Station F450.
The arrays were scanned using an Affymetrix GeneArray scanner
2500. The raw microarray feature intensities (RAS scores) were
processed using the Affymetrix Genotyping Tools software package
GCOS/GDAS (Affymetrix) to derive SNP genotypes, marker order
and linear chromosomal location.
Genotyping using microsatellite markers
STS genotyping was performed using fluorescent dye-labelled
microsatellite markers (MWG Biotech, Ebersberg, Germany). PCR
products were run out on an ABI 3100 Genetic Analyser and analysed
using Genotyper software (Applied Biosystems, Foster City, CA,
USA). All genotypes that were unclear were repeated until a con-
sistent genotype was obtained. Markers that were uninformative
were excluded from further analysis.
Sequencing of candidate genes
Genes within the conserved haplotype were identified from the
Ensembl database (http://www.ensembl.org/Homo_sapiens/index.
html) and candidate genes were selected. Exons were amplified
and sequenced using oligonucleotide primers (MWG Biotech).
The fluorescent dideoxy sequencing products were run out on an
ABI 3100 and analysed for base pair changes by Sequencher v4.5
(GeneCodes Corp., Ann Arbor, MI, USA).
Results
SNP genotyping
SNP genotyping was performed on 27 individuals. The aver-
age SNP genotype call rate was 99.1% (range 98.09–99.88%),
providing on average 9957 genotypes per individual. None
of the males typed was assigned a heterozygous state for any
of the SNPs mapping to the X chromosome. Overall, 0.36% of
markers displayed non-Mendelian transmission and a further
0.82% of markers displayed a presumptive transmission error.
This implies that the overall genotyping error rate associated
with the 10K v2.0 SNP array was in the order of 1.18%.
Linkage analysis and locus identification
SNP genotype data was directly imported into the linkage
analysis programme Merlin and analysed initially for NPL.
Owing to the size of the family being studied, the SNP chip
data was analysed by initially splitting the family into two
(individual II:6 and children treated as separate kindred).
NPL analysis identified an extensive region with positive
LOD scores across chromosome 9p (Fig. 3). The maximum
NPL LOD score detected when the family was split into two
was 1.31, with the maximum LOD score achievable using this
model of 1.54. Although dividing the family was essential if
we were to analyse data from all 27 individuals genotyped, we
also analysed the data as a single core pedigree as an affected-
only study of 18 individuals, which permitted NPL and para-
metric analyses. There was anNPL peak on chromosome 9p of
1.21 (with a maximum potential LOD score of 1.43) and a
parametric peak LOD score of 2.4 (Fig. 4). Only one other
region had positive LOD scores of 0.48 (NPL) and 1.29 (para-
metric) at 21qtel, but linkage was subsequently excluded using
STS markers, which demonstrated that the affected indivi-
duals lacked a common haplotype and generated negative
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LOD scores (data not shown, submitted for review). All other
chromosomes showed consistently negative LOD scores on
parametric analysis using Merlin (data not shown, submitted
for review).
Forty microsatellite markers were used to fine map the
region on chromosome 9p, generating a two-point LOD
score peak of 2.41 (u = 0) at D9S1878 (maximum Slink
potential LOD score of 2.88). The peak multipoint LOD
score of 3.02 occurred between D9S52 and D9S1805
(Table 2). Haplotype analysis revealed a critical recombina-
tion event at the centromeric and telomeric end of the
haplotype in the recreated individual III:5 (Fig. 1). We
believe that the telomeric cross-over event is robust, as it
is present in all three offspring (IV:3,5,6) who inherited
this chromosome, whereas the centromeric cross-over is
present in the same offspring and two siblings (III:6,7).
The telomeric flanking marker is D9S2154 and centromeric
marker is D9S1874. These recombinant events narrow the
conserved haplotype to a 12 cM (11 Mb) region at
9p13.2–21.3.
Candidate gene selection and
mutation screening
Bioinformatic analysis of the region has identified 103
known genes. These have been prioritized according to
Fig. 3 Graphical representation of multipoint LOD scores using the non-parametric linkage analysis programme Merlin in a split
family model. The maximum LOD score detected was 1.34 and no other region had a LOD score > 0.8 (maximum achievable = 1.54).
No other chromosomes generated LOD scores > 0.8.
Fig. 4 Graphical representation of multipoint LOD scores from an affecteds-only analysis of the kindred comparing non-parametric (NPL)
and parametric linkage data generated by Merlin. The maximum NPL LOD score of 1.21 was detected at 9p (with a maximum
potential LOD score of 1.43) and a parametric peak of 2.4.
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their expression in the brain and possible role in pathogenesis.
Three genes were chosen as candidates for initial mutation
screening, but no mutation was found by direct sequencing.
Dynactin 3 was selected, as it is a subunit of the multi-
protein dynactin complex that is involved in retrograde axo-
nal transport in the motoneuron (Waterman-Storer, 1997).
This process is disrupted in motoneuron disease, and
recent studies have shown the presence of point mutations
in the p150 subunit of the dynactin complex (Puls et al., 2003;
Munch, 2004). Mutations in other genes in the complex
may also cause disruption to axonal transport in the moto-
neuron. KIF24 was chosen, as the kinesin protein superfamily
is involved in many cellular functions including vesicle
transport, axonal transport of neurofilaments and micro-
tubule dynamics (Xia et al., 2003; Serbus, 2005). Mutations
in KIF5A have been described in an autosomal dominant
hereditary spastic paraplegia (HSP) family (Fichera et al.,
2004). This is a motoneuron disorder that indicates
that mutations in this superfamily of proteins may lead to
disruption of axonal transport in the motoneuron. BAG1
is involved in the ubiquitin proteasome pathway and
binds with HSP70, coordinating the chaperoning of
proteins targeted for degradation in the 26S proteasome
(Takayama, 2001; Alberti, 2003). The presence of ubiquitin
positive inclusions in motoneuron disease pathology
indicates that this process may be disrupted (Ikeda and
Tsuchiya, 2004) and, therefore, singles out BAG1 as a
candidate gene.
Conclusions
ALS and FTD are both rapidly fatal late-onset neurodegen-
erative disorders where the majority of cases are sporadic and
families suitable for linkage are extremely rare. Some families
with autosomal dominant disease have an overlapping
clinical phenotype that includes features of ALS and FTD
in a spectrum. Here, we report a large Dutch kindred with
late-onset ALS–FTD that demonstrates linkage to chromo-
some 9p13.2–21.3. Recombination has narrowed the region
shared between the families to 11 Mb containing 103 known
genes in this region. These will be screened for mutations and
prioritized on the basis of their expression in the central
nervous system and potential role in the pathogenesis of ALS.
If other ALS or FTD families are linked to this locus, it
suggests that mutations in the causative gene may be a sig-
nificant cause of familial and sporadic ALS and FTD. The
identification of another ALS–FTD gene will enable more
families to undergo predictive and prenatal testing. It will
also allow the development of further transgenic and cellular
models of ALS that will hopefully advance our understanding
of disease mechanisms and help in developing more effective
therapies for ALS.
Subsequent to the completion of this work the authors have
learnt that an unrelated Swedish kindred with ALS–FTD has
been linked to 9p21.3–p13.3 with a haplotype spanning 14
Mb. This overlaps precisely with our locus and reduces the
shared region to 9.8 Mb (Mortia et al., 2006).
Electronic database information
Accession numbers and URLs for data in this article are as
follows:
 Online Mendelian Inheritance in Man (OMIM), http://
www.ncbi.nlm.nih.gov/Omim/ (for background informa-
tion on loci)
 Center for Medical Genetics, Marshfield Medical Research
Foundation, http://research.marshfieldclinic.org/genetics/
(for marker and position)
 UK Human Genome Mapping Project Resource Centre,
http://www.hgmp.mrc.ac.uk/Bioinformatics/ (for marker
and gene position)
 UCSC Human Genome Project Working Draft, http://
genome.ucsc.edu/
Table 2 Two-point and multipoint LOD scores between the disease locus and chromosome 9p markers
Marker Genetic position Two-point LOD scores Multipoint
(cM) u = 0 u = 0.1 u = 0.2 u = 0.3 u = 0.4 LOD scores
1121 37.0 1.65 1.24 0.82 0.42 0.12 0.97
126 37.1 0.51 0.34 0.20 0.09 0.02 0.99
2154 42.0 0.1 0.28 0.23 0.12 0.03 0.92
169 42.2 1.97 1.47 0.95 0.47 0.12 2.69
104 42.9 2.19 1.71 1.20 0.68 0.21 2.96
248 44.8 1.76 1.32 0.86 0.44 0.12 3.02
304 48.9 2.14 1.73 1.26 0.75 0.25 3.01
1878 49.6 2.41 1.9 1.34 0.76 0.24 3.02
1817 49.7 2.08 1.59 1.08 0.58 0.17 3.02
1791 51.8 2.23 1.73 1.20 0.67 0.20 2.77
1874 52.3 0.17 0.65 0.50 0.27 0.08 0.70
1862 52.4 0.38 0.8 0.66 0.4 0.13 0.62
1800 60.9 0.89 0.41 0.15 0.04 0.01 0.49
284 67.2 0.38 0.08 0.13 0.09 0.03 0.64
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 National Centre for Biotechnology Information (NCBI),
http://www.ncbi.nlm.nih.gov/mapview/ (for marker and
gene position)
 Genome Database, http://www.gdb.org
Supplementary material
Supplementary data are available at Brain Online.
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